MA42266A - Agent thérapeutique contre la fibrose - Google Patents

Agent thérapeutique contre la fibrose

Info

Publication number
MA42266A
MA42266A MA042266A MA42266A MA42266A MA 42266 A MA42266 A MA 42266A MA 042266 A MA042266 A MA 042266A MA 42266 A MA42266 A MA 42266A MA 42266 A MA42266 A MA 42266A
Authority
MA
Morocco
Prior art keywords
therapeutic agent
agent against
against fibrosis
fibrosis
therapeutic
Prior art date
Application number
MA042266A
Other languages
English (en)
Inventor
Akio Fujioka
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of MA42266A publication Critical patent/MA42266A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA042266A 2015-06-25 2016-06-24 Agent thérapeutique contre la fibrose MA42266A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2015127788 2015-06-25

Publications (1)

Publication Number Publication Date
MA42266A true MA42266A (fr) 2018-05-02

Family

ID=57585165

Family Applications (1)

Application Number Title Priority Date Filing Date
MA042266A MA42266A (fr) 2015-06-25 2016-06-24 Agent thérapeutique contre la fibrose

Country Status (20)

Country Link
US (4) US10449189B2 (fr)
EP (2) EP3973962A1 (fr)
JP (3) JP6974167B2 (fr)
KR (1) KR102647942B1 (fr)
CN (2) CN107708697B (fr)
AU (1) AU2016284531B2 (fr)
BR (1) BR112017028137B1 (fr)
CA (1) CA2990791A1 (fr)
DK (1) DK3315131T3 (fr)
ES (1) ES2928684T3 (fr)
HU (1) HUE060732T2 (fr)
MA (1) MA42266A (fr)
MX (2) MX381792B (fr)
MY (1) MY191219A (fr)
PH (1) PH12017502322B1 (fr)
PL (1) PL3315131T3 (fr)
PT (1) PT3315131T (fr)
RU (1) RU2729630C2 (fr)
SG (2) SG11201709260TA (fr)
WO (1) WO2016208744A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007139608A1 (fr) 2006-03-14 2007-12-06 Ceres, Inc. Séquences de nucléotides et polypeptides correspondants conférant un taux de croissance et une biomasse modulés à des plantes cultivées dans des conditions salines
US12152246B2 (en) 2006-03-14 2024-11-26 Ceres, Inc. Nucleotide sequences and corresponding polypeptides conferring modulated growth rate and biomass in plants grown in saline conditions
KR102323255B1 (ko) 2017-02-15 2021-11-08 다이호야쿠힌고교 가부시키가이샤 의약 조성물
US12280045B2 (en) 2017-09-08 2025-04-22 Taiho Pharmaceutical Co., Ltd. Antitumor agent and antitumor effect potentiator
KR20210060465A (ko) 2018-09-18 2021-05-26 다이호야쿠힌고교 가부시키가이샤 아실티오우레아 화합물과 아비라테론의 병용 요법
TWI872203B (zh) 2020-02-14 2025-02-11 日商大鵬藥品工業股份有限公司 醯基硫脲化合物的製造方法
CN115177636A (zh) * 2022-07-18 2022-10-14 陕西科美致尚生物科技有限公司 一种用于治疗前列腺钙化的组合物及其制备方法与应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1074264T3 (da) 1998-04-28 2008-11-24 Toshikazu Nakamura Inhibitorer for neovaskularisering
JP2003238592A (ja) * 2001-12-13 2003-08-27 Japan Tobacco Inc 組織及び血管の再生のための医薬及びその方法
AU2006265835B2 (en) 2005-06-30 2012-05-03 Amgen Inc. Bis-aryl kinase inhibitors and their use in the treatment of inflammation, angiogenesis and cancer
WO2007064797A2 (fr) 2005-11-30 2007-06-07 Vertex Pharmaceuticals Incorporated Inhibiteurs de c-met et leurs utilisations
ZA200804681B (en) * 2005-11-30 2009-11-25 Vertex Pharma Inc Inhibitors of C-Met and uses thereof
CA2676173A1 (fr) 2007-02-16 2008-08-28 Amgen Inc. Ketones heterocyclyles contenant de l'azote et leur utilisation comme inhibiteurs de c-met
AU2008315746A1 (en) 2007-10-25 2009-04-30 Astrazeneca Ab Pyridine and pyrazine derivatives useful in the treatment of cell proliferative disorders
ES2423851T3 (es) 2008-04-10 2013-09-24 Taiho Pharmaceutical Co., Ltd. Compuesto de aciltiourea o sal del mismo y uso del mismo
UY32049A (es) * 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
EA025304B1 (ru) 2010-02-03 2016-12-30 Инсайт Холдингс Корпорейшн ИМИДАЗО[1,2-b][1,2,4]ТРИАЗИНЫ В КАЧЕСТВЕ c-Met ИНГИБИТОРОВ
ES2715611T3 (es) 2010-05-17 2019-06-05 Incozen Therapeutics Pvt Ltd Compuestos novedosos de 3H-imidazo[4,5-b]piridina-3,5-disustituida y 3H-[1,2,3]triazolo[4,5-b]piridina 3,5-disustituida como moduladores de proteína cinasas
TWI594986B (zh) 2011-12-28 2017-08-11 Taiho Pharmaceutical Co Ltd Antineoplastic agent effect enhancer
RU2494470C1 (ru) * 2012-04-04 2013-09-27 Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" (ООО "Саентифик Фьючер Менеджмент") Способ лечения фиброза легких
US9149471B2 (en) 2013-09-30 2015-10-06 National University Corporation Tokyo University Of Agriculture And Technology Therapeutic agent for osteoporosis

Also Published As

Publication number Publication date
US20200009128A1 (en) 2020-01-09
US20180289690A1 (en) 2018-10-11
MX2017016774A (es) 2018-05-14
JP2023076632A (ja) 2023-06-01
DK3315131T3 (da) 2022-11-14
SG11201709260TA (en) 2018-01-30
AU2016284531A1 (en) 2017-11-30
US20220047572A1 (en) 2022-02-17
BR112017028137A2 (pt) 2018-08-28
WO2016208744A1 (fr) 2016-12-29
MY191219A (en) 2022-06-09
US11690838B2 (en) 2023-07-04
EP3315131B1 (fr) 2022-09-14
HUE060732T2 (hu) 2023-04-28
RU2729630C2 (ru) 2020-08-11
US11191759B2 (en) 2021-12-07
PL3315131T3 (pl) 2022-12-12
CN107708697A (zh) 2018-02-16
CA2990791A1 (fr) 2016-12-29
JPWO2016208744A1 (ja) 2018-04-12
ES2928684T3 (es) 2022-11-21
JP2022009994A (ja) 2022-01-14
PH12017502322A1 (en) 2018-06-25
BR112017028137B1 (pt) 2023-04-04
RU2017145271A (ru) 2019-07-25
KR20180021682A (ko) 2018-03-05
KR102647942B1 (ko) 2024-03-14
MX2020012989A (es) 2021-02-16
JP7258985B2 (ja) 2023-04-17
EP3973962A1 (fr) 2022-03-30
HK1245639A1 (zh) 2018-08-31
AU2016284531B2 (en) 2020-06-04
JP7498827B2 (ja) 2024-06-12
CN107708697B (zh) 2021-02-09
SG10201912684TA (en) 2020-03-30
US20200297716A1 (en) 2020-09-24
CN112716952A (zh) 2021-04-30
MX381792B (es) 2025-03-13
EP3315131A4 (fr) 2019-02-27
EP3315131A1 (fr) 2018-05-02
JP6974167B2 (ja) 2021-12-01
US10449189B2 (en) 2019-10-22
RU2017145271A3 (fr) 2019-12-02
PT3315131T (pt) 2022-10-26
US10695340B2 (en) 2020-06-30
PH12017502322B1 (en) 2023-08-30

Similar Documents

Publication Publication Date Title
FIC20240025I1 (fi) Momelotinibi, mukaanlukien momelotinibidihydrokloridimonohydraatti
HRP20181692T1 (hr) Liječenje fibroze
IL250685A0 (en) Medicinal substance induces cytotoxicity
EP3314027A4 (fr) Oligonucléotides thérapeutiques
SG10201912416QA (en) Therapeutic agents
BR112016021682A2 (pt) cenicriviroc para o tratamento da fibrose
DK3289080T3 (da) Genterapi til autosomalt dominante sygdomme
DK3262066T4 (da) Genterapi
GB201509893D0 (en) Therapeutic agents
ZA201600079B (en) Active mixtures
MA39483A (fr) Agents thérapeutiques cibles
GB201517263D0 (en) Therapeutic agents
EP3315131A4 (fr) Agent thérapeutique contre la fibrose
PL3318267T3 (pl) Środek leczniczy do leczenia zespołu huntera
GB201509885D0 (en) Therapeutic agents
DK3393478T3 (da) Kombinationsterapi
EP3362091A4 (fr) Polythérapie
EP3308781A4 (fr) Agent hypotenseur
EP3541931A4 (fr) Traitement combiné fractal
DE112016003293A5 (de) Feuerlöscher
GB201509888D0 (en) Therapeutic agents
DK3329004T3 (da) Terapeutiske oligonukleotider
EP3334447A4 (fr) Conjugués médicament-cck2r
BR112017011897A2 (pt) métodos de tratamento da fibrose
EP3659609A4 (fr) Agent thérapeutique contre la fibrose